Effect of atorvastatin on paraoxonase1 (PON1) and oxidative status.
It has been proposed that paraoxonase1 (PON1), a high density lipoprotein (HDL)-associated esterase/lactonase, has anti-atherosclerotic properties. The activity of PON1 is influenced by PON1 polymorphisms. However, the influence of PON1 polymorphisms on PON1 activity and oxidative stress in response to lipid-lowering drugs remains poorly understood. The objective of the present study was to investigate the effects of atorvastatin on PON1 activity and oxidative status. The influence of PON1 polymorphisms on PON1 activity and oxidative status in response to atorvastatin treatment was also evaluated. In total, 22 hypercholesterolemic patients were treated with atorvastatin at a dose of 10 mg/day for 3 months. Lipid profile, lipid oxidation markers (malondialdehyde (MDA), conjugated diene (CD), total peroxides (TP)), total antioxidant substance (TAS), oxidative stress index (OSI), and paraoxonase1 activity were determined before and after treatment. L55M, Q192R, and T(-107)C PON1 polymorphisms were also determined. Atorvastatin treatment significantly reduced the levels of total cholesterol (24.5%), low density lipoprotein (LDL) cholesterol (25.4%), triglycerides (24.4%), CD (4.4%), MDA (15.2%), TP (13.0%) and OSI (24.0%), and significantly increased the levels of TAS (27.3%), and PON1 activity (14.0%). Interestingly, the increase in PON1 activity and the reduction in oxidative stress in response to atorvastatin were influenced only by the PON1 T-107C polymorphism. Atorvastatin treatment improved the lipid profile, lipid oxidation, and oxidative/antioxidative status markers including the activity of PON1 towards paraoxon. These beneficial effects may be attributed to the antioxidant properties of statins and the increase in PON1 activity. The increase in PON1 activity was enhanced by the PON1 T-107C polymorphism.
Nagila
Amar
A
Fishtail Hospital and Research Center, Pokhara Gandaki Zone, Nepal.
Permpongpaiboon
Thinnakorn
T
Tantrarongroj
Soontharee
S
Porapakkham
Pornwalee
P
Chinwattana
Kultira
K
Deakin
Sara
S
Porntadavity
Sureerut
S
D000924:Anticholesteremic Agents / Q000494:pharmacology*; D043303:Aryldialkylphosphatase / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D000069059:Atorvastatin; D006538:Heptanoic Acids / Q000494:pharmacology*; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy* / Q000503:physiopathology; D015227:Lipid Peroxidation / Q000187:drug effects; D008055:Lipids / Q000097:blood; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects; D010261:Paraoxon / Q000378:metabolism; D011110:Polymorphism, Genetic; D011758:Pyrroles / Q000494:pharmacology*
D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D008055:Lipids; D011758:Pyrroles; D000069059:Atorvastatin; D043303:Aryldialkylphosphatase; C468406:PON1 protein, human; D010261:Paraoxon